FLT3 and acute myeloid leukemia: Additionally, by combining cellular and biochemical profiling data, relevant activities and selectivities of several kinase inhibitors were discovered that may be explored to expand the application of kinase inhibitors for other therapeutic indications, such as the tropomyosin receptor kinase (TRK) inhibitor entrectinib for the treatment of FMS-like tyrosine kinase 3 (FLT3)-mutant acute myeloid leukemia (AML).